



REQUEST FOR EXPRESSIONS OF INTEREST:

Projects to Identify, Develop and Evaluate Therapeutics for Diabetic Complications

BACKGROUND AND PURPOSE OF REQUEST

JDRF is committed to translation of research findings towards clinical results.

JDRF is soliciting expressions of interest for identification, development or pre-clinical testing of novel therapeutic approaches designed to prevent, treat, reverse or ameliorate the following complications of type 1 diabetes: retinopathy, with a higher priority on non-proliferative retinopathy or progression from nonproliferative to proliferative stages, and all stages of diabetic neuropathy or nephropathy.

SPECIFIC GOALS OF REQUEST

Expressions of interest are sought for applicants interested in identifying compounds for a specific drug target via library screening or other approaches, developing novel compounds to the stage of pre-clinical testing or proposing carefully designed pilot and feasibility studies in proven animal model systems that should closely reflect human complications and accurately model human clinical trials. This request seeks to provide support towards the pre-clinical translation of novel or existing therapeutic compounds. Where appropriate, academic investigators with existing animal models relevant to type 1 diabetes may collaborate with an industry partner or other academic group with access to candidate therapeutics and state-of-the art techniques. Where appropriate, mechanistic information should be derived from the results.

Examples of therapeutics to be considered under this request include, but are not limited to:

- Small molecule compounds
- Biologics
- Cell-based therapies
- Novel drug combinations or delivery modalities
- Device-based interventions
- Investigators with ideas or resources that might benefit this initiative should also submit their ideas via an expression of interest.

Expressions of intent should be no more than two pages in length including, where applicable, the following information:

- Name, title and institution of principal investigator, co-investigator and / or key collaborator
- Brief details of drug target, assay, therapeutic or animal model proposed
- Brief details of approach proposed, including rationale and references to published or preliminary data (preliminary data need not be presented in detail)
- Brief details of endpoints proposed, with emphasis on functional endpoints
- Short and long-term development goals
- Willingness to test other compounds using a proposed animal model as part of a potential network
- Total estimated budget and project duration (not to exceed 24 months)

Enquiries in this area should be referred to Helen Nickerson Ph.D. hnickerson@jdrf.org ; tel: +1-212-479-7522).

KEY DATES:

- Expressions of interest should be submitted as attached pdf via e-mail to Helen Nickerson Ph.D. hnickerson@jdrf.org under the subject line "EOI-PCT" no later than November 21, 2007 at 11.59 p.m. EST.
- Submitted expressions of interest will be acknowledged with brief responses as to their suitability for further development by the JDRF Complications Program no later than December 15, 2007.

For a directory of all JDRF grant opportunities visit the JDRF website at www.jdrf.org

The [Information for Applicants](#) section of our website will provide application information, instructions and deadlines